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Abstract: There are numerous obstacles to genomic 
medicine. These include the large number of rare and 
novel genomic variants per individual. The American 
College of Medical Genetics and Genomics (ACMG) 
has recommended that all pathogenic variants in 56 
gene-disease pairs that are identified incidentally in a 
genomic test be offered to the patient (Green et al., 2013, 
PMID: 23788249). We considered an expanded list of 
112 actionable gene-disease pairs, ones where medical 
intervention is possible to prevent or detect disease early. 
We estimate the rate of these incidental findings (IFs) 
in European and African Ancestry groups. However, 
we found high discordance between classifications of 
expert reviewers. We have reported both inconsistency 
across labs in variant classification and a bias towards 
overcall ing pathogenicity (Amendola et  al . ,  2015, 
PMID: 25637381). Thus, there is a need to standardize 
classification of genomic variants in medical sequencing. 
To date genomics laboratories have used non-standard 
classification systems. The ACMG published guidelines 
for variant classif ication for Mendelian disorders 
designed to increase consistency among labs (Richards 
et al., 2015, PMID: 25741868). The Clinical Sequencing 
Exploratory Research (CSER) Consortium evaluated 
the use of these rules by nine of the CLIA laboratories 
supporting CSER projects, considering 99 germline 
variants. The results were examined to evaluate intra-
laboratory differences between variant classifications 
using the labs own criteria vs. adopting ACMG criteria 
and inter-laboratory differences using either the lab’s 
own system or the ACMG guidelines. Agreement among 
labs did not differ whether using the laboratory specific 
vs. ACMG criteria (P=0.9); i.e., the ACMG criteria did 
not yield more consistent variant classification in this 
exercise. We further analyzed sources of disagreement 
in the use of the ACMG criteria and identified causes of 
variance in classifications. In addition to providing useful 
analyses of how variant classifications approaches vary 
among laboratories, these data should allow clarification 
and refinement of the ACMG criteria that may increase 
consistency in variant classification.
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Abstract: The Rare and Undiagnosed Diseases Diagnostic 
Service (RUDDS) is a Clinical Genomic Diagnostic 
Pipeline operating within the clinical service at Genetic 
Services of Western Australia (GSWA). GSWA has 
provided a state-wide service for clinical genetic care 
for more than 25 years and it serves a population of 2.5 
million people. It includes paediatric, adult, prenatal and 
familial cancer services in metropolitan and regional WA. 
Within this framework, and in partnership with the Office 
of Population Health Genomics, Diagnostic Genomics at 
PathWest and others, it is delivering a clinically integrated 
pipeline. This service is aligned to the WA Rare Diseases 
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Strategic Framework 2015-2018 to address the unmet 
need of the diagnostic odyssey of those living with rare and 
undiagnosed diseases. It is: (I) delivered in a patient-centric 
manner that is resonant with the patient journey; (II) offers 
multiple options including non-genetic testing; monogenic 
and genomic (targeted and whole exome) analysis, 
and matchmaking; (III) is synchronous with precision 
phenotyping methods, including 3D facial analysis, and 
phenotype-enabled decision support; (IV) captures new 
knowledge, including multiple expert review; (V) has 
multiple points for entry, exit and re-entry to allow people 
access to information they can use, when they want to receive 
it; (VI) draws on the clarity gained from the extremity of 
rare diseases to provide insights for more common diseases; 
(VII) is integrated with current translational genomic 
research activities; and (VIII) is designed for flexibility for 
integrative generation of, and integration with, further 
clinical research including for diagnostics, community 
engagement, policy and models of care.
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Abstract: Genetic factors contribute to risk for many common 
traits and diseases affecting reproduction and fertility. We have 
used genome-wide association (GWA) studies to understand 
the genetic architecture and discover genomic regions 
associated with risk for endometriosis, dizygotic twinning, 
age at menarche and age at menopause. The next steps are 
to determine how DNA sequence variation alters regulation 
and/or function of specific genes and pathways to increase 
disease risk. Multiple approaches are required to interpret the 
genetic association results, identify the specific genes likely 
to be responsible, and obtain the necessary genomic evidence 
connecting the genetic results to the target genes. Strategies 
include fine mapping, functional annotation, genomics, and 
target gene identification through gene expression, epigenetics, 
and cell-based studies to define direct interactions between 
causal single nucleotide polymorphisms (SNPs) and target 
genes. GWA and replication studies have identified seven 
genomic regions with strong evidence for association with 
endometriosis risk. The target tissue for functional effects 
is not known, but current theories suggest changes in the 
endometrium. We are conducting studies of gene expression 
and epigenetic regulation in samples of endometrium in 
carriers of the risk alleles. Development of applications to 
use GWA data for risk prediction and studies of comorbidity 
also provide valuable insights into the genetic architecture of 
endometriosis and overlap in risk with other conditions such as 
ovarian cancer. Multidisciplinary studies combining genetics, 
genomics, functional biology, and clinical research will be 
essential better understand disease biology and translate the 
new knowledge into better outcomes for patients.
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